Posted on July 26, 2016
Children born with cleft lip/palate go through extensive treatments that usually begin before their first birthday. Most treatment plans include surgery to repair the orofacial cleft, which will increase the child’s verbal communication abilities, self-esteem and overall confidence. Unfortunately, a one-time surgery is rare. Many children require revision surgeries to create the correct alignment, symmetry and normal facial movements. As a result, health providers are constantly looking for ways to decrease the number of revision surgeries required for children with CL/P.
An article in the current issue of The Cleft Palate–Craniofacial Journal explores the reasons behind the multiple follow-up surgeries required by the condition as well as how their frequency may be reduced. In order to determine a percentage of revision surgeries, the authors conducted an electronic search of previously published articles relating to cleft lip surgery. Of the 3,034 articles identified, 45 met their study criteria, which yielded a total of 4,210 patients involved. Overall, the research showed that there was a 0% to 100% instance of revision surgeries among the various studies. However, the researchers were unable to determine the burden of care (amount and intensity of all treatments) experienced by the patients.
When analyzing the specifics of each study, authors found that revision surgeries could be affected by the following: isolated cleft lip compared with cleft lip and cleft palate corrections, the portion of the lip where the surgery was conducted (specifically, the vermilion or vermilo-cutaneous junction), and the follow-up duration, with more revision surgeries resulting from longer follow-up times. The authors also found that the quality of the initial surgery plays a very important role in revisions, especially when dealing with the vermilion junction, and it was determined that closing the vermilion could reduce the need for revision surgeries.
This study has provided a strong foundation for future studies on cleft lip revision surgery. The authors concluded that a new population-based study should be conducted for more definitive findings on the burden of care for unilateral cleft lip. Such a study would help to further reduce the current reliance on surgical care and improve outcomes for patients worldwide.
Full text of the article, “The Burden of Care for Children With Unilateral Cleft Lip: A Systematic Review of Revision Surgery,” The Cleft Palate–Craniofacial Journal, Vol. 53, No. 4, 2016, is available at http://www.cpcjournal.org/doi/full/10.1597/14-202.
Posted on July 26, 2016
The bacteria that live in dental plaque and contribute to tooth decay often resist traditional antimicrobial treatment, as they can “hide” within a sticky biofilm matrix, a glue-like polymer scaffold.
A new strategy conceived by University of Pennsylvania researchers took a more sophisticated approach. Instead of simply applying an antibiotic to the teeth, they took advantage of the pH-sensitive and enzyme-like properties of iron-containing nanoparticles to catalyze the activity of hydrogen peroxide, a commonly used natural antiseptic. The activated hydrogen peroxide produced free radicals that were able to simultaneously degrade the biofilm matrix and kill the bacteria within, significantly reducing plaque and preventing the tooth decay, or cavities, in an animal model.
“Even using a very low concentration of hydrogen peroxide, the process was incredibly effective at disrupting the biofilm,” said Hyun (Michel) Koo, a professor in the Penn School of Dental Medicine’s Department of Orthodontics and divisions of Pediatric Dentistry and Community Oral Health and the senior author of the study, which was published in the journal Biomaterials. “Adding nanoparticles increased the efficiency of bacterial killing more than 5,000-fold.”
The paper’s lead author was Lizeng Gao, a postdoctoral researcher in Koo’s lab. Coauthors were Yuan Liu, Dongyeop Kim, Yong Li, and Geelsu Hwang, all of Koo’s lab, as well as David Cormode, an assistant professor of radiology and bioengineering with appointments in Penn’s Perelman School of Medicine and School of Engineering and Applied Science, and Pratap C. Naha, a postdoctoral fellow in Cormode’s lab.
The work built off a seminal finding by Gao and colleagues, published in 2007 in Nature Nanotechnology, showing that nanoparticles, long believed to be biologically and chemically inert, could in fact possess enzyme-like properties. In that study, Gao showed that an iron oxide nanoparticle behaved similarly to a peroxidase, an enzyme found naturally that catalyzes oxidative reactions, often using hydrogen peroxide.
When Gao joined Koo’s lab in 2013, he proposed using these nanoparticles in an oral setting, as the oxidation of hydrogen peroxide produces free radicals that can kill bacteria.
“When he first presented it to me, I was very skeptical,” Koo said, “because these free radicals can also damage healthy tissue. But then he refuted that and told me this is different because the nanoparticles’ activity is dependent on pH.”
Gao had found that the nanoparticles had no catalytic activity at neutral or near-neutral pH of 6.5 or 7, physiological values typically found in blood or in a healthy mouth. But when pH was acidic, closer to 5, they become highly active and can rapidly produce free radicals.
The scenario was ideal for targeting plaque, which can produce an acidic microenvironment when exposed to sugars.
Gao and Koo reached out to Cormode, who had experience working with iron oxide nanoparticles in a radiological imaging context, to help them synthesize, characterize and test the effectiveness of the nanoparticles, several forms of which are already FDA-approved for imaging in humans.
Beginning with in vitro studies, which involved growing a biofilm containing the cavity-causing bacteria Streptococcus mutans on a tooth-enamel-like surface and then exposing it to sugar, the researchers confirmed that the nanoparticles adhered to the biofilm, were retained even after treatment stopped and could effectively catalyze hydrogen peroxide in acidic conditions.
They also showed that the nanoparticles’ reaction with a 1% or less hydrogen peroxide solution was remarkably effective at killing bacteria, wiping out more than 99.9% of the S mutans in the biofilm within 5 minutes, an efficacy more than 5,000 times greater than using hydrogen peroxide alone. Even more promising, they demonstrated that the treatment regimen, involving a 30-second topical treatment of the nanoparticles followed by a 30-second treatment with hydrogen peroxide, could break down the biofilm matrix components, essentially removing the protective sticky scaffold.
Moving to an animal model, they applied the nanoparticles and hydrogen peroxide topically to the teeth of rats, which can develop tooth decay when infected with S mutans just as humans do. Twice-a-day, one-minute treatments for three weeks significantly reduced the onset and severity of carious lesions, the clinical term for tooth decay, compared to the control or treatment with hydrogen peroxide alone. The researchers observed no adverse effects on the gum or oral soft tissues from the treatment.
“It’s very promising,” said Koo. “The efficacy and toxicity need to be validated in clinical studies, but I think the potential is there.”
Among the attractive features of the platform is the fact that the components are relatively inexpensive.
“If you look at the amount you would need for a dose, you’re looking at something like 5 milligrams,” Cormode said. “It’s a tiny amount of material, and the nanoparticles are fairly easily synthesize, so we’re talking about a cost of cents per dose.”
In addition, the platform uses a concentration of hydrogen peroxide, 1%, which is lower than many currently available tooth-whitening systems that use 3% to 10% concentrations, minimizing the chance of negative side effects.
Looking ahead, Gao, Koo, Cormode, and colleagues hope to continue refining and improving upon the effectiveness of the nanoparticle platform to fight biofilms.
“We’re studying the role of nanoparticle coatings, composition, size, and so forth so we can engineer the particles for even better performance,” Cormode said.
The study was funded by the International Association for Dental Research/GlaxoSmithKline Innovation in Oral Health Award, National Science Foundation, and University of Pennsylvania Research Foundation.
Posted on July 26, 2016
Small businesses seeking to commercialize health-related technologies in the medical or life science sector can learn how to access more than $870 million in federal funding during the Department of Health and Human Services Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) conference, which will be held in Orlando, Florida, on Nov. 15-17, 2016.
“This flagship SBIR/STTR event provides the chance for entrepreneurs and researchers to meet one-on-one with federal representatives, network with each other, and learn how the National Institutes of Health helps small businesses forge new relationships that can help bring technologies and discoveries to market,” said Matthew Portnoy, PhD, the NIH SBIR/STTR program coordinator. “We are hoping businesses take advantage of this opportunity and register to attend the conference.”
The 18th Annual HHS SBIR/STTR Conference, titled Shining a Light on Small Business Innovation, will be co-hosted by the State University System of Florida and the University of Central Florida, Orlando, and is expected to attract nearly 800 participants from around the country.
One of the key objectives of the SBIR and STTR programs is to foster and encourage participation in innovation and entrepreneurship by women and socially and economically disadvantaged people. The NIH keynote speaker will be Eliseo J. Pérez-Stable, MD, director of the National Institute on Minority Health and Health Disparities, and interactive workshops and sessions will feature presentations by women-owned and minority-owned businesses supported by the SBIR/STTR programs.
Attendees will include representatives from NIH, Centers for Disease Control and Prevention, US Food and Drug Administration, Administration for Community Living, Office of the HHS Inspector General, and the Small Business Administration. Early bird registration is available until August 31, 2016, and a draft agenda is available online at: https://www.regonline.com/sbirsttrorlando.
Posted on July 25, 2016
In an article published today in The Journal of the American Dental Association (JADA), experts from the Centers for Disease Control and Prevention (CDC) and the Organization for Safety, Asepsis and Prevention (OSAP) provide best practices for responsible antibiotic use in dentistry.
Dentists write nearly 26 million prescriptions for antibiotics each year, which amounts to 10% of all antibiotic prescriptions filled in outpatient pharmacies. While the extent is unknown, experts are concerned that unnecessary antibiotic prescribing occurs in dental settings. To assist throughout the entire antibiotic prescribing process, CDC and OSAP have developed a checklist to guide dentists through pretreatment, prescribing, and patient and staff education.
Patients are encouraged to use the following Do’s and Don’ts for ensuring patient safety when they or their loved ones are prescribed antibiotics at the dentist.
Posted on July 22, 2016
Registration is open for the 41st Annual Meeting of the American Academy of Esthetic Dentistry (AAED), which will be held at the Monarch Beach Resort Hotel in Dana Point, California, from August 3-5.
Educational sessions will explore the meeting's theme, "Point Counterpoint: The Controversies & Innovations in Esthetic Dentistry." View the full program with session abstracts, speaker details, and more on the AAED's mobile-friendly platform at https://www.messageblocks.com/aaedam16.
The register for the meeting, go to http://www.estheticacademy.org/event/aaed2016.
Posted on July 21, 2016
Throughout 2016, Geistlich Biomaterials will be celebrating a triad of milestones that make us who we are. 20 years of Geistlich Bio-Gide®, 30 years of Geistlich Bio-Oss® and over 1,000 published studies demonstrating their clinical efficacy in practice.
With these 3, comes our Jubilee!
The history of Geistlich Biomaterials spans more than 160 years and is built on proud spirit of innovation and the pioneering achievements of its biomaterials. The Jubilee Anniversary for Geistlich has been focused on giving a voice to our partnering dental professional in sharing their regenerative experiences, knowledge and success. So in support of this celebration, Geistlich has established a website dedicated to celebrating the Jubilee and providing a global platform that encourages dental professionals in research and clinical practice to share their experiences and clinical cases using Geistlich biomaterials with the world.
Be a part of it by visiting: www.geistlich-jubilee.com
To date, hundreds of practitioners have supported in the “Sharing Success” campaign by submitting their best publications, clinical cases and inspiring statements involving Geistlich Biomaterials. At the conclusion of the Jubilee year, all contributions to the website will be reviewed and winners within each category will be chosen. Prizes include a feature on the Geistlich Jubilee Wall of Fame and a chance to win an Apple iPad. Nine iPads will be raffled, each installed with Geistlich’s Patient Information Package on Regenerative Dentistry.
To further celebrate the Jubilee, Geistlich is hosting a Jubilee Webinar World Tour featuring 5 (five) educational webinars with leading clinicians from around the world.
These webinars are FREE and interactive.
NOW AVAILABLE ON-DEMAND
• Anthony Sclar (USA) – Ridge Preservation
• István Urbán (Hungary) – Sausage Technique
• Prof. Ki-Tae Koo (South Korea) – Ridge Preservation
• Dr. Paulo Fernando (Brazil) – Soft-Tissue Management
September 15, 2016 at 6:00pm EDT
• Prof. Ronald Jung & Prof. Christoph Hämmerlee (Switzerland) - GBR Revisited
October 20, 2016 at 1:00pm EDT
Can’t make the live date? All of the webinars will also be available on-demand after the live date.
We thank our customers for their collaboration, trust and above all…for the success we share.
Posted on July 21, 2016
Edgar Jimenez has been named an Accredited Fellow in the American Academy of Cosmetic Dentistry (AACD). He is the 70th individual to achieve Fellowship in the Academy and only the sixth Accredited Fellow Laboratory Technician in the history of the AACD.
The purpose of Fellowship is to provide the highest level of achievement for members in accordance with the AACD's mission of education and excellence.
Jimenez began his career over 20 years ago as an in-office dental technician. During that time, he was able to partner with the practitioner and patient, which facilitated unparalleled treatment results. He also learned the importance of a total team approach, which he still practices today. Now Jimenez owns and operates a full service boutique lab, Edgar Jimenez Dental Studio, located in North Oaks, Minnesota where he specializes in full-mouth reconstruction and cosmetic smile design.
A member of the American Academy of Cosmetic Dentistry since 2006, Jimenez has presented to university students in Cuba as part of the AACD’s University Outreach program, and he is an avid supporter of the AACD Charitable Foundation’s Give Back a Smile program.
“Mr. Jimenez’s commitment to responsible esthetics and cosmetic dentistry is undeniable with his most recent achievement as an AACD Accredited Fellow,” said AACD Fellowship Chair Bradley J. Olson, DDS, FAACD. “Our Accredited Fellow members must complete one of the most rigorous, yet life-changing journeys of their career—and of their lives.”
He will be honored for this achievement at AACD 2017 in Las Vegas on April 21, 2017.
Posted on July 20, 2016
S-Ray Incorporated announced that it has launched on its website a "Testing the Waters" campaign at: http://s-rayinc.com/invest.
The campaign is intended to gauge potential investor interest in a going public transaction – an IPO via Regulation A Plus Tier II. S-Ray is measuring public support for a possible offering by targeting the general investment and dental industry communities as well as socially responsible investors as it seeks to raise up to $50 million of additional capital to support growth strategies and operational goals. S-Ray’s intention is to file a Regulation A Plus with the Securities and Exchange Commission (SEC) once the "Testing the Waters" campaign reaches the threshold of $1 million.
In the past, only qualified investors, venture capitalists, and private equity firms had the opportunity to invest via special securities in private-to-public transactions. This changed in June 2015 with the passage of the JOBS Act in April 2012 and the SEC's release of the regulations governing the new rules.
S-Ray intends to participate in these new rules under Regulation A Plus Tier II. But before any investment into a Regulation A Plus offering can occur, the company must first qualify its potential offering with Federal regulators and launch its "Testing the Waters" campaign to gauge market interest. The campaign will target potential investors through email, social media campaigns and by inviting investors to participate.
“We have been anticipating the next major steps of growth for our company,” said Steve Baird, S-Ray Incorporated’s CEO. “So we welcome the possibilities afforded by an IPO via Regulation A Plus Tier II.”
No money or other consideration is being solicited in S-Ray’s “Testing the Waters” campaign, and, if sent, in response, it will not be accepted. Offers to buy securities cannot be accepted, and no sales of securities will be made or commitment to purchase accepted until qualification of the offering statement by the SEC and the approval of any other required government or regulatory agency. An indication of interest made by a prospective investor is non-binding and involves no obligation or commitment of any kind. No offer of securities will be made without a qualified offering circular.
Any eventual Regulation A Plus offering will be presented to investors in the order they participate in the "Testing the Waters" campaign. Potential investors can indicate their interest in the campaign at S-Ray’s dedicated webpage: http://s-rayinc.com/invest/testing-the-waters-campaign/testing-the-waters-campaign-potential-investors/.
Posted on July 20, 2016
ATLANTA – Kool Smiles, a leading provider of quality dental care in underserved communities nationwide, has announced its first annual My Kool Smiles Scholarship Fund essay contest, sponsored by the Benevis Foundation. A $5,000 scholarship will be awarded to one eligible U.S. student who submits the winning essay response to the question, “How can dental health contribute to the well-being of families and children?”
The dental health essay contest runs from July 18 to September 30, 2016. Students may apply online at https://mykoolsmiles.com/l/scholarship.
“Kool Smiles created this scholarship fund as a way to support talented students who are passionate about making a difference in dental care,” said Dr. Dale Mayfield, Chief Dental Officer for Kool Smiles. “Our 2016 essay question reflects the idea that dental health can impact so much more than a child’s smile. We look forward to reading what students have to say about this important topic.”
The $5,000 scholarship will be awarded to a student whose essay on dental health demonstrates clarity of content, originality, creativity and persuasiveness. Essay submissions will be evaluated by a panel of Kool Smiles dentists and staff.
In addition to the essay, eligible students must complete and submit an online application by September 30, 2016. The winner will be announced on November 15, 2016.
Applicants must either be in the final year of high school, enrolled as an undergraduate, or a graduate student in an accredited U.S. institution. Students must be considered in academic "Good Standing" at their current institution, with a minimum cumulative Grade Point Average (GPA) of 3.0 or higher (or equivalent). Applicants should carefully review the scholarship program Official Rules to be sure they qualify.
For more information about the My Kool Smiles Scholarship Fund, please visit https://mykoolsmiles.com/l/scholarship.
About Kool Smiles
Kool Smiles is dedicated to creating a world of happy, healthy smiles. As a leading dental care provider, Kool Smiles’ mission is to improve lives by providing high quality dental care in a fun, compassionate environment. Kool Smiles dentists are proud to offer care to kids and adults with almost any insurance plan, including State Children’s Health Insurance Programs (SCHIP), Medicaid and Tricare. Kool Smiles, with support from the Benevis Foundation, also provides oral health education programs through partnerships with community schools and organizations. For more information, please visit www.mykoolsmiles.com.
Posted on July 20, 2016
MELVILLE, NY, July 20, 2016 – Henry Schein, Inc. (Nasdaq: HSIC) joined the Alpha Omega International Dental Fraternity’s (AO) Columbus, Ohio, chapter in recognizing 13 area oral health professionals for their participation in a program that provides free dental care to Holocaust survivors in need.
The Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program was launched in November 2014 in response to the White House’s call to action to help Holocaust survivors age with dignity and respect. To date, the program has provided free oral care to more than 200 economically vulnerable Holocaust survivors across North America, including more than a dozen in Columbus.
The participating dentists were honored at a recent reception hosted by Jewish Family Services in Columbus. U.S. Senator Sherrod Brown (D-OH) congratulated the honorees, AO, and Henry Schein Cares in a Certificate of Commendation presented at the reception.
“The Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program’s impact would not be possible without the dedicated dental professionals who so generously give their time and talent to serving the oral health needs of Holocaust survivors,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Henry Schein stands proudly with the Alpha Omega International Dental Fraternity to honor and thank the Columbus chapter for its commitment to this deserving group of people.”
The initiative provides care to people identified by the network of Jewish Family and Children’s Service agencies or other identified partner organizations, as well as people of any faith who were victims of Nazi persecution and meet the program’s other eligibility requirements. In addition to financial need, patient participation is prioritized by three critical factors: the elimination of pain, restoration of function, and lack of dental coverage. Participating clinicians determine each patient’s scope of care.
This program fills a critical need for many of the 120,000 Holocaust survivors living in the U.S., one quarter of whom live in poverty. Survivors often have special oral health needs, as many suffered from prolonged nutritional deprivation and had little to no dental care access as children during World War II. The program currently operates in 15 geographies, including Columbus, Chicago, New York City, the New York/New Jersey metropolitan area, Boston, Philadelphia, Detroit, Seattle, Montreal, Toronto, Atlanta, Calgary, Los Angeles, Winnipeg, and Dallas.
“Participating in the Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program has been an incredible experience for our members and we have learned so much from the Holocaust survivors we have treated,” said Dr. Shaun Rotenberg, Ambassador of AO’s Columbus chapter. “It is our honor to help them in whatever manner we can, and we look forward to continuing to participate in this wonderful program.”
Dentists honored at the event were: Kevin Albert, Anny Almasanu, Brad Blair, Aaron Carroll, Katie Carroll, Marc Hollander, Fredric Kaufman, Brad Kripke, Mark Levy, Shaun Rotenberg, Rob Steiner, Jeff Tilson, and Eric Zidel.
“Alpha Omega’s Columbus chapter has shown that kindness and charity can have an incredible impact on the health and happiness of people in need,” said program Co-Chair and AO Past International President Dr. Avi Wurman, DDS. “These oral health practitioners have helped Holocaust survivors eat without pain and smile proudly, and we thank them for upholding the ideals to which Alpha Omega’s members aspire.”
The Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program has received generous financial support from The Claire Friedlander Family Foundation and the Curt C. & Else Silberman Foundation. Additional support has been provided by the Henry Schein Cares Foundation, Inc., Bedford Health Care Solutions, The Dr. Edward B. Shils Entrepreneurial Fund, Inc., the Wagner Family
Foundation, and the Slomo and Cindy Silvian Foundation, Inc.
Please watch this video for more information about the Alpha Omega-Henry Schein Cares Holocaust Survivors Oral Health Program.
About Alpha Omega International Dental Fraternity
The Alpha Omega International Dental Fraternity (AO) is the oldest international Jewish dental and medical organization. Founded in 1907 at the University of Maryland School of Dental Medicine, AO has expanded into an international community of dental professionals who are guided by the tenets of professionalism, fraternalism, and commitment to Judaic values.
With over 100 alumni and student chapters in 10 countries, AO members embrace the spirit of Tikkun Olam, or healing the world through charitable endeavors. As healers, our members strive to make their communities better. For more information, please contact Heidi Weber, AO Executive Director, at firstname.lastname@example.org.
About Henry Schein Cares
Henry Schein Cares stands on four pillars: engaging Team Schein Members to reach their potential, ensuring accountability by extending ethical business practices to all levels within Henry Schein, promoting environmental sustainability, and expanding access to health care for underserved and at-risk communities around the world. Health care activities supported by Henry Schein Cares focus on three main areas: advancing wellness, building capacity in the delivery of health care services, and assisting in emergency preparedness and relief.
Firmly rooted in a deep commitment to social responsibility and the concept of enlightened self-interest championed by Benjamin Franklin, the philosophy behind Henry Schein Cares is a vision of “doing well by doing good.” Through the work of Henry Schein Cares to enhance access to care for those in need, the Company believes that it is furthering its long-term success. “Helping Health Happen Blog” is a platform for health care professionals to share their volunteer experiences delivering assistance to those in need globally. To read more about how Henry Schein Cares is making a difference, please visit our blog: www.helpinghealthhappen.org.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the S&P 500® and the Nasdaq 100® indexes, Henry Schein employs nearly 19,000 Team Schein Members and serves more than one million customers.
The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 110,000 branded products and Henry Schein private-brand products in stock, as well as more than 150,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.
Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 33 countries. The Company's sales reached a record $10.6 billion in 2015, and have grown at a compound annual rate of approximately 15 percent since Henry Schein became a public company in 1995. For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein and @HenrySchein on Twitter.